Quantcast
Home > Quotes > SGEN
SGEN

Seattle Genetics, Inc. Common Stock (SGEN) Quote & Summary Data

$53.05
*  
1.79
3.26%
Get SGEN Alerts
*Delayed - data as of Nov. 14, 2018 14:30 ET  -  Find a broker to begin trading SGEN now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    SGEN Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 52.92 / $ 53.06
1 Year Target
84.5
Today's High / Low
$ 55.63 / $ 52.175
Share Volume
917,675
50 Day Avg. Daily Volume
1,041,542
Previous Close
$ 54.84
52 Week High / Low
$ 84.37 / $ 47.75
Market Cap
8,495,739,358
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -1.09
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.91

Intraday Chart

News for SGEN

Shares Traded

Share Volume:
917,675
50 Day Avg. Daily Volume:
1,041,542

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.09

Trading Range

The current last sale of $53.05 is 11.10% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 55.63 $ 84.37
 Low: $ 52.175 $ 47.75

ETFs with SGEN as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
2.54% Principal Healthcare Innovators Index ETF (BTEC) -4.32 (-12.18%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

Seattle Genetics is a biotechnology company focused on the development and commercialization of targeted therapies for the treatment of cancer. Our marketed product ADCETRIS┬«, or brentuximab vedotin, is approved by the United States Food and Drug Administration, or FDA, and the European Commission for four indications, encompassing several settings for the treatment of relapsed Hodgkin lymphoma, for relapsed systemic anaplastic large cell lymphoma, or sALCL, and for certain types of cutaneous T-cell lymphoma, or CTCL. ADCETRIS is commercially available in 70 countries, including in the United States, Canada, members of the European Union and Japan. We are collaborating with Takeda Pharmaceutical Company Limited, or Takeda, to develop and commercialize ADCETRIS on a global basis.  ... More ...  


Risk Grade

Where does SGEN fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 55.07
Open Date:
Nov. 14, 2018
Close Price:
$ 54.84
Close Date:
Nov. 13, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x